In the largest ever study with a total of 140,012 human subjects, the KRAS LCS6 variant did not increase the risk of ovarian cancer or breast cancer, regardless of the BRAC1/2 status; null results were also obtained for associations with overall survival for ovarian cancer, breast cancer, and all other previously reported associations for these cancers46. Here, KRAS is linked to breast cancer.